Prograf Official FDA information, side effects and uses. A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Prograf. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.In a mass balance study of IV administered radiolabeled tacrolimus to 6 healthy volunteers, the mean recovery of radiolabel was 77.8 12.7%. Fecal elimination accounted for 92.4 1.0% and the elimination half-life based on radioactivity was 48.1 15.9 hours whereas it was 43.5 11.6 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.029 0.015 L/hr/kg and clearance of tacrolimus was 0.029 0.009 L/hr/kg. When administered PO, the mean recovery of the radiolabel was 94.9 30.7%. Fecal elimination accounted for 92.6 30.7%, urinary elimination accounted for 2.3 1.1% and the elimination half-life based on radioactivity was 31.9 10.5 hours whereas it was 48.4 12.3 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.226 0.116 L/hr/kg and clearance of tacrolimus 0.172 0.088 L/hr/kg.
